in patients with nephropathy due to type 2 diabetes,[1] hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours).[2][edit] avapro and enalapril with diureticIrbesartan is also available in a combination formulation with avapro and enalapril low dose thiazide diuretic, invariably hydrochlorothiazide, to achieve hydrochlorothiazide.

mainly for the treatment of hypertension. Irbesartan may also delay progression of diabetic nephropathy and avapro and enalapril also indicated for avapro and enalapril treatment of hypertension. Irbesartan was developed by Sanofi avapro and enalapril (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names to avapro and enalapril preparations, including avapro and enalapril Karvezide, Avalide and Avapro HCT.[edit] References^ Lewis EJ, Hunsicker LG, Clarke WR, Berl T, avapro and enalapril MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. (2001). "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes,[1] hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 avapro and enalapril Combination with diureticIrbesartan is also available in a combination formulation with a low dose thiazide diuretic, invariably hydrochlorothiazide, to achieve an additive antihypertensive effect.

number 138402-11-6ATC code C09CA04PubChem 3749DrugBank APRD00413Chemical dataFormula C25H28N6OMol. mass 428.53SMILES.